We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Dedicated Blood DNA Collection Tube Receives European Marketing Approval

By LabMedica International staff writers
Posted on 13 Feb 2014

Image: The PAXgene Blood DNA Tube (Photo courtesy of PreAnalytiX GmbH).

Image: The PAXgene Blood DNA Tube (Photo courtesy of PreAnalytiX GmbH).

A new collection tube for routine clinical use that was designed to preserve DNA in blood samples was recently certified for use as a diagnostic product in Europe.

The PreAnalytiX GmbH (Feldbachstrasse, Switzerland) PAXgene Blood DNA Tube provides a means for the collection of whole blood for the isolation of genomic DNA in a closed, evacuated system. Blood is collected under a standard phlebotomy protocol into an evacuated tube that contains potassium-EDTA additive. Complete isolation of DNA is carried out using manual or automated methods such as salting out precipitation, magnetic beads, or silica membrane-based technologies.

The 2.5 milliliter PAXgene Blood DNA Tube stabilizes genomic DNA with validated time and temperature parameters. The tube incorporates workflow efficiency features including a two-dimensional bar code on the label and a tube closure that clearly identifies this unique DNA collection tube.

The PAXgene tube, which recently received the European Union's CE marking IVD certification for sale in Europe was developed as part of a joint venture between Becton Dickinson and Company ((Franklin Lakes, NJ, USA) and QIAGEN (Venlo, The Netherlands).

“The validated performance data we provide to clinical scientists for the PAXgene Blood DNA Tube should reduce the chances of preanalytical error, ensuring the best quality sample for accurate IVD test performance and for blood DNA storage related to the identification of new biomarkers of disease or drug actions,” said Frank Augello, general manager of PreAnalytiX GmbH.

Related Links:
PreAnalytiX GmbH
Becton Dickinson and Company
QIAGEN

Visit expo >

Gold Member

Flocked Fiber Swabs

Puritan® Patented HydraFlock®

Online QC Software
Acusera 24•7

New

Pipette Calibration System

Artel PCS®

New

Prefilled Tubes

Prefilled 5.0ml Tubes

Latest Technology News

Channels

Molecular Diagnostics

view channel

Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more

Patented Isothermal Amplification Chemistry Advances Decentralized Testing

Molecular diagnostics offer high sensitivity for pathogen detection but typically rely on thermal cycling and specialized instruments, limiting their use outside centralized laboratories.... Read more

$Image: Unlike standard tests that detect bacteria directly, host-response assays measure the body\'s immune response, potentially enabling earlier infection detection and risk identification (image credit: Adobe Stock)$

Finger-Prick Blood Test Aids Early Tuberculosis Detection and Risk Stratification

Household contacts of people with tuberculosis face an estimated 2% risk of developing disease, yet most are asymptomatic at the time of screening. Early-stage cases are often missed because symptom checks... Read more

Image: MyProstateScore2.0 – Active Surveillance Visual Abstract (Jeffrey J. Tosoian et al, Journal of Urology (2026) DOI: 10.1097/ju.0000000000005095)

Urine Test Beats MRI in Identifying Prostate Cancer Upgrading During Active Surveillance

Active surveillance is common for men with low-risk prostate cancer, yet deciding when to repeat biopsy remains challenging. Prostate-specific antigen (PSA) testing and magnetic resonance imaging (MRI)... Read more

Hematology

view channel

Image: Graphical abstract (Waclawiczek A, Leppä AM, Renders S, et al. Cell Stem Cell, 2026. doi:10.1016/j.stem.2026.04.012)

Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more

Advanced CBC-Derived Indices Integrated into Hematology Platforms

Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more

Blood Test Enables Early Detection of Multiple Myeloma Relapse

Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read more

Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching

CareDx (Brisbane, CA, USA) has introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO genotyping solution unveiled at the European Federation for Immunogenetics (EFI) Conference 2026.... Read more

Immunology

view channel

Biomarkers and Molecular Testing Advance Precision Allergy Care

Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more

Image: Schematic of Mpox diagnostic methods.(A) Artificial intelligence (AI)-enhanced image classification can be leveraged to classify lesions concerning for Mpox, particularly in low resource settings where specialists (i.e., infectious disease specialists or dermatologists) are not available. (B) Clinical specimens (including nasal swabs, lesion swabs, or serum samples) can be used for molecular or biochemical confirmation of Mpox infection. (C) Rapidly, field-deployable devices or assays can be developed using various strategies(Mpox) diagnostic methods (Yilgic D, Ergonul O, Tasoglu S. Mpox diagnosis at POC. Trends in Biotechnology. DOI: 0.1016/j.tibtech.2025.04.015)

Point-of-Care Tests Could Expand Access to Mpox Diagnosis

Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more

Image: Graphical abstract (Turano PS, Akbulut E, Dewald HK, et al. Cell Reports (2026). DOI: 10.1016/j.celrep.2025.116795)

T-Cell Senescence Profiling May Predict CAR T Responses

Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read more

Finger-Prick Lateral Flow Test Detects Sepsis Biomarkers at Point of Care

Sepsis remains a time-critical condition in which rapid risk assessment is often hindered by reliance on centralized laboratory testing. The global burden is substantial, with an estimated 166 million... Read more

Microbiology

view channel

Image: Biosensor for tuberculosis detection (photo courtesy of UPV)

Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour

Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more

Image: Graphical abstract (Qin, Y. et al., Cell Rep Med 7: 102761 (2026). DOI: 10.1016/j.xcrm.2026.102761)

Oral–Gut Microbiome Signatures Identify Early Gastric Cancer

Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more

Image: Magnetic field-enhanced alignment and detection of hemozoin in lysed infected red blood cells using polarizing microscopy (photo courtesy of Dickson Mwenda Kinyua, Kirinyaga University)

Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria

Microscopy of blood smears remains a cornerstone for malaria diagnosis but can be slow, stain-dependent, and operator intensive. With more than 200 million infections and over 600,000 deaths annually,... Read more

Gut Microbiome Test Predicts Melanoma Recurrence After Surgery

Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more

Pathology

view channel

FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification

Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more

Image: Tissue sample spatial analysis (on left) and standard H&E image (on right) (Photo courtesy of QIMR Berghofer Medical Research Institute)

New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides

Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read more

Image: SPARK overview, data structure and study design (Trost, F., Zhang, B., Aring, I. et al. https://doi.org/10.1038/s41591-026-04357-y)

AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes

The digital transformation of pathology is expanding how cancers are evaluated in routine practice. Artificial intelligence (AI) is increasingly applied to routinely collected histological tissue sections,... Read more

New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease

Diabetic kidney disease is a leading cause of chronic kidney disease and end-stage kidney disease, affecting 20%–40% of people with diabetes and more than 107 million individuals worldwide as of 2021.... Read more

Technology

view channel

Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing

Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read more

Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response

Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more

New Platform Captures Extracellular Vesicles for Early Cancer Detection

Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read more

Microfluidic Single-Cell Assay Predicts Breast Cancer Risk

Risk stratification for breast cancer remains imprecise, as population-based models and breast density can over- or underestimate individual risk, potentially leading to over- or under-screening.... Read more

Industry

view channel

Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio

Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more

FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy

Endocrine therapy resistance remains a significant challenge in estrogen receptor–positive, human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer, where tumor evolution can limit... Read more

CareDx Expands Precision Oncology Portfolio with Naveris Acquisition

CareDx Inc. (Brisbane, CA, USA), a precision medicine company advancing clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, has entered a definitive agreement... Read more

Thermo Fisher Scientific to Sell Microbiology Business to Astorg

Thermo Fisher Scientific has signed a definitive agreement to sell its microbiology business to Astorg for approximately $1.075 billion, comprising cash and a $50 million seller note. Announced on April... Read more